Castrate Resistant Advanced Prostate

Hormone Naive

Non-Metastatic

Metastatic

Non-Metastatic

No Trials Currently Available

IRB # 11268: Salvage radiation + enzalutamide/placebo for recurrent prostate cancer

New Trial Coming Soon

IRB # 10241: Phase II study involving enzalutamide and biopsy for research

IRB # 10241: Phase II study of cabazitaxel + enzalutamide

IRB # 11227: Phase II study of pembrolizumab after progression of enzalutamide

IRB # 11025: Phase II study of niraparib + AR-targeted therapies

IRB # 15561: Phase I/II study of BI836845 added to enzalutamide

IRB # 15651: Phase I/II study of BI836845 added to enzalutamide

IRB # 16093: A Phase II Trial of Pembrolizumab (MK-3475) in mCRPC

IRB # 16294: Phase I Safety and Tolerability of ZEN003694 w/enzalutamide

IRB # 15921: INTERVAL: Intense exercise for survival among men with mCRPC

IRB # 15944: Falls in Elderly Men Taking Enzalutamide

IRB # 16294: Enrolment on Hold

IRB # 16539: Phase II study of niraparib in Men with DNA-Repair anomalies

IRB # 16446: Phase I study of niraparib + AR-targeted therapies

IRB # 9204: Stand Up To Cancer Biopsy for research

IRB # 16093: A Phase II Trial of Pembrolizumab (MK-3475) in mCRPC

IRB # 16294: Phase I Safety and Tolerability of ZEN003694 w/enzalutamide

IRB # 16446: Phase I study of niraparib + AR-targeted therapies

IRB # 15921: INTERVAL: Intense exercise for survival among men with mCRPC

IRB # 15944: Falls in Elderly Men Taking Enzalutamide

Supportive Care/Biomarker

New Trial Coming Soon

IRB # 11268: Salvage radiation + enzalutamide/placebo for recurrent prostate cancer

New Trial Coming Soon

IRB # 10241: Phase II study involving enzalutamide and biopsy for research

IRB # 11227: Phase II study of cabazitaxel + enzalutamide

IRB # 11025: Phase II study of pembrolizumab after progression of enzalutamide

IRB # 15561: Phase I/II study of BI836845 added to enzalutamide

IRB # 15651: Phase I/II study of BI836845 added to enzalutamide

IRB # 16093: A Phase II Trial of Pembrolizumab (MK-3475) in mCRPC

IRB # 16294: Phase I Safety and Tolerability of ZEN003694 w/enzalutamide

IRB # 16446: Phase I study of niraparib + AR-targeted therapies

IRB # 15921: INTERVAL: Intense exercise for survival among men with mCRPC

IRB # 15944: Falls in Elderly Men Taking Enzalutamide

http://www.ohsu.edu/research/rda/so/knight.php

10/26/2017